Loading patent…
AssigneeThe Regents of the University of California
InventorsRobert Stern, Gregory I. Frost, Anthony Csóka, Tim M. Wong
Estimating the term…
The invention is based on the discovery of methods for purification of an acid active hyaluronidase found in human plasma (hpHAse), including both biochemical and immunoaffinity purification methods. The method of immunoaffinity purification of the invention is based on the discovery of a method for identifying antibodies that specifically bind native hpHAse (anti-native hpHAse antibodies), and anti-native hpHAse antibodies identified by this screening method. The invention also features an assay for sensitive detection of HAse activity using biotinylated hyaluronic acid (bHA). Purification and characterization of hpHAse lead to the inventors' additional discovery that hpHAse is encoded by the LuCa-1 gene, which gene is present in the human chromosome at 3p21.3, a region associated with tumor suppression. The invention additionally features methods of treating tumor-bearing patients by administration of hpHAse and/or transformation of cells with hpHAse-encoding DNA.
A method of reducing tumor growth in a patient having a cancer having a decreased level of human plasma hyaluronidase activity compared to the level of human plasma hyaluronidase activity in a non-cancerous cell, the method comprising administering to the patient a construct comprising a nucleotide sequence that encodes a human plasma hyaluronidase polypeptide, and a promoter sequence functional in a eukaryotic cell, said promoter sequence operably linked to said nucleotide sequence, said administering resulting in production of an effective amount of human plasma hyaluronidase in the patient to reduce tumor growth.
A method of reducing tumor growth in a patient having a cancer associated with a defective LuCal gene, the method comprising administering to the patient a construct comprising a nucleotide sequence that encodes a human plasma hyaluronidase polypeptide, and a promoter sequence functional in a eukaryotic cell, said promoter sequence operably linked to said nucleotide sequence, said administering resulting in production of an effective amount of human plasma hyaluronidase in the patient to reduce tumor growth.
A method of reducing tumor metastasis in a patient having a cancer associated with a defective LuCa1 gene, the method comprising administering to the patient a construct comprising a nucleotide sequence that encodes a human plasma hyaluronidase polypeptide, and a promoter sequence functional in a eukaryotic cell, said promoter sequence operably linked to said nucleotide sequence, said administering resulting in production of an effective amount of human plasma hyaluronidase in the patient to reduce tumor metastasis.
A method of reducing tumor metastasis in a patient having a cancer having a decreased level of human plasma hyaluronidase activity compared to the level of human plasma hyaluronidase activity in a non-cancerous cell, the method comprising administering to the patient a construct comprising a nucleotide sequence that encodes a human plasma hyaluronidase polypeptide, and a promoter sequence functional in a eukaryotic cell, said promoter sequence operably linked to said nucleotide sequence, wherein said administering resulting in production of an effective amount of human plasma hyaluronidase in the patient to reduce tumor metastasis.
Dependencies are inferred from the claim text.